Click for best price
NonCancerous Blood Disease Treatment Market Size, Share 2023
This report aims to provide a comprehensive presentation of the global market for Non-Cancerous Blood Disease Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Cancerous Blood Disease Treatment. This report contains market size and forecasts of Non-Cancerous Blood Disease Treatment in global, including the following market information:
Global Non-Cancerous Blood Disease Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Non-Cancerous Blood Disease Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Antibiotics Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Non-Cancerous Blood Disease Treatment include SANOFI, Novo Nordisk A/S, Novartis AG, Pfizer Inc., Amgen Inc., Alexion Pharmaceuticals, Inc., Bayer AG, Bristol Myers Squibb Company and F. Hoffmann-La Roche Ltd., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-Cancerous Blood Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Cancerous Blood Disease Treatment Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Non-Cancerous Blood Disease Treatment Market Segment Percentages, by Type, 2022 (%)
Antibiotics
Blood Transfusion
Infusion Therapy
Dietary Supplements or Chelators
Others
Global Non-Cancerous Blood Disease Treatment Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Non-Cancerous Blood Disease Treatment Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Non-Cancerous Blood Disease Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Non-Cancerous Blood Disease Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Cancerous Blood Disease Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-Cancerous Blood Disease Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
SANOFI
Novo Nordisk A/S
Novartis AG
Pfizer Inc.
Amgen Inc.
Alexion Pharmaceuticals, Inc.
Bayer AG
Bristol Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Takeda Pharmaceutical Company Limited
CSL Behring
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-Cancerous Blood Disease Treatment, market overview.
Chapter 2: Global Non-Cancerous Blood Disease Treatment market size in revenue.
Chapter 3: Detailed analysis of Non-Cancerous Blood Disease Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-Cancerous Blood Disease Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Non-Cancerous Blood Disease Treatment Market, Global Outlook and Forecast 2023-2029 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
64 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-Cancerous Blood Disease Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Cancerous Blood Disease Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Cancerous Blood Disease Treatment Overall Market Size
2.1 Global Non-Cancerous Blood Disease Treatment Market Size: 2022 VS 2029
2.2 Global Non-Cancerous Blood Disease Treatment Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Cancerous Blood Disease Treatment Players in Global Market
3.2 Top Global Non-Cancerous Blood Disease Treatment Companies Ranked by Revenue
3.3 Global Non-Cancerous Blood Disease Treatment Revenue by Companies
3.4 Top 3 and Top 5 Non-Cancerous Blood Disease Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-Cancerous Blood Disease Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Cancerous Blood Disease Treatment Players in Global Market
3.6.1 List of Global Tier 1 Non-Cancerous Blood Disease Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Cancerous Blood Disease Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Non-Cancerous Blood Disease Treatment Market Size Markets, 2022 & 2029
4.1.2 Antibiotics
4.1.3 Blood Transfusion
4.1.4 Infusion Therapy
4.1.5 Dietary Supplements or Chelators
4.1.6 Others
4.2 By Type - Global Non-Cancerous Blood Disease Treatment Revenue & Forecasts
4.2.1 By Type - Global Non-Cancerous Blood Disease Treatment Revenue, 2018-2023
4.2.2 By Type - Global Non-Cancerous Blood Disease Treatment Revenue, 2024-2029
4.2.3 By Type - Global Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-Cancerous Blood Disease Treatment Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Non-Cancerous Blood Disease Treatment Revenue & Forecasts
5.2.1 By Application - Global Non-Cancerous Blood Disease Treatment Revenue, 2018-2023
5.2.2 By Application - Global Non-Cancerous Blood Disease Treatment Revenue, 2024-2029
5.2.3 By Application - Global Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Non-Cancerous Blood Disease Treatment Market Size, 2022 & 2029
6.2 By Region - Global Non-Cancerous Blood Disease Treatment Revenue & Forecasts
6.2.1 By Region - Global Non-Cancerous Blood Disease Treatment Revenue, 2018-2023
6.2.2 By Region - Global Non-Cancerous Blood Disease Treatment Revenue, 2024-2029
6.2.3 By Region - Global Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Non-Cancerous Blood Disease Treatment Revenue, 2018-2029
6.3.2 US Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.3.3 Canada Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.3.4 Mexico Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Non-Cancerous Blood Disease Treatment Revenue, 2018-2029
6.4.2 Germany Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.4.3 France Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.4.4 U.K. Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.4.5 Italy Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.4.6 Russia Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.4.7 Nordic Countries Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.4.8 Benelux Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Non-Cancerous Blood Disease Treatment Revenue, 2018-2029
6.5.2 China Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.5.3 Japan Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.5.4 South Korea Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.5.5 Southeast Asia Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.5.6 India Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Non-Cancerous Blood Disease Treatment Revenue, 2018-2029
6.6.2 Brazil Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.6.3 Argentina Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Cancerous Blood Disease Treatment Revenue, 2018-2029
6.7.2 Turkey Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.7.3 Israel Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.7.4 Saudi Arabia Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
6.7.5 UAE Non-Cancerous Blood Disease Treatment Market Size, 2018-2029
7 Non-Cancerous Blood Disease Treatment Companies Profiles
7.1 SANOFI
7.1.1 SANOFI Company Summary
7.1.2 SANOFI Business Overview
7.1.3 SANOFI Non-Cancerous Blood Disease Treatment Major Product Offerings
7.1.4 SANOFI Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.1.5 SANOFI Key News & Latest Developments
7.2 Novo Nordisk A/S
7.2.1 Novo Nordisk A/S Company Summary
7.2.2 Novo Nordisk A/S Business Overview
7.2.3 Novo Nordisk A/S Non-Cancerous Blood Disease Treatment Major Product Offerings
7.2.4 Novo Nordisk A/S Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.2.5 Novo Nordisk A/S Key News & Latest Developments
7.3 Novartis AG
7.3.1 Novartis AG Company Summary
7.3.2 Novartis AG Business Overview
7.3.3 Novartis AG Non-Cancerous Blood Disease Treatment Major Product Offerings
7.3.4 Novartis AG Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.3.5 Novartis AG Key News & Latest Developments
7.4 Pfizer Inc.
7.4.1 Pfizer Inc. Company Summary
7.4.2 Pfizer Inc. Business Overview
7.4.3 Pfizer Inc. Non-Cancerous Blood Disease Treatment Major Product Offerings
7.4.4 Pfizer Inc. Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.4.5 Pfizer Inc. Key News & Latest Developments
7.5 Amgen Inc.
7.5.1 Amgen Inc. Company Summary
7.5.2 Amgen Inc. Business Overview
7.5.3 Amgen Inc. Non-Cancerous Blood Disease Treatment Major Product Offerings
7.5.4 Amgen Inc. Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.5.5 Amgen Inc. Key News & Latest Developments
7.6 Alexion Pharmaceuticals, Inc.
7.6.1 Alexion Pharmaceuticals, Inc. Company Summary
7.6.2 Alexion Pharmaceuticals, Inc. Business Overview
7.6.3 Alexion Pharmaceuticals, Inc. Non-Cancerous Blood Disease Treatment Major Product Offerings
7.6.4 Alexion Pharmaceuticals, Inc. Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.6.5 Alexion Pharmaceuticals, Inc. Key News & Latest Developments
7.7 Bayer AG
7.7.1 Bayer AG Company Summary
7.7.2 Bayer AG Business Overview
7.7.3 Bayer AG Non-Cancerous Blood Disease Treatment Major Product Offerings
7.7.4 Bayer AG Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.7.5 Bayer AG Key News & Latest Developments
7.8 Bristol Myers Squibb Company
7.8.1 Bristol Myers Squibb Company Company Summary
7.8.2 Bristol Myers Squibb Company Business Overview
7.8.3 Bristol Myers Squibb Company Non-Cancerous Blood Disease Treatment Major Product Offerings
7.8.4 Bristol Myers Squibb Company Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.8.5 Bristol Myers Squibb Company Key News & Latest Developments
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 F. Hoffmann-La Roche Ltd. Company Summary
7.9.2 F. Hoffmann-La Roche Ltd. Business Overview
7.9.3 F. Hoffmann-La Roche Ltd. Non-Cancerous Blood Disease Treatment Major Product Offerings
7.9.4 F. Hoffmann-La Roche Ltd. Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.9.5 F. Hoffmann-La Roche Ltd. Key News & Latest Developments
7.10 Takeda Pharmaceutical Company Limited
7.10.1 Takeda Pharmaceutical Company Limited Company Summary
7.10.2 Takeda Pharmaceutical Company Limited Business Overview
7.10.3 Takeda Pharmaceutical Company Limited Non-Cancerous Blood Disease Treatment Major Product Offerings
7.10.4 Takeda Pharmaceutical Company Limited Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.10.5 Takeda Pharmaceutical Company Limited Key News & Latest Developments
7.11 CSL Behring
7.11.1 CSL Behring Company Summary
7.11.2 CSL Behring Business Overview
7.11.3 CSL Behring Non-Cancerous Blood Disease Treatment Major Product Offerings
7.11.4 CSL Behring Non-Cancerous Blood Disease Treatment Revenue in Global Market (2018-2023)
7.11.5 CSL Behring Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-Cancerous Blood Disease Treatment Market Opportunities & Trends in Global Market
Table 2. Non-Cancerous Blood Disease Treatment Market Drivers in Global Market
Table 3. Non-Cancerous Blood Disease Treatment Market Restraints in Global Market
Table 4. Key Players of Non-Cancerous Blood Disease Treatment in Global Market
Table 5. Top Non-Cancerous Blood Disease Treatment Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-Cancerous Blood Disease Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Non-Cancerous Blood Disease Treatment Revenue Share by Companies, 2018-2023
Table 8. Global Companies Non-Cancerous Blood Disease Treatment Product Type
Table 9. List of Global Tier 1 Non-Cancerous Blood Disease Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Cancerous Blood Disease Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Non-Cancerous Blood Disease Treatment Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Non-Cancerous Blood Disease Treatment Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Non-Cancerous Blood Disease Treatment Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Non-Cancerous Blood Disease Treatment Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Non-Cancerous Blood Disease Treatment Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Non-Cancerous Blood Disease Treatment Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2024-2029
Table 30. SANOFI Company Summary
Table 31. SANOFI Non-Cancerous Blood Disease Treatment Product Offerings
Table 32. SANOFI Non-Cancerous Blood Disease Treatment Revenue (US$, Mn) & (2018-2023)
Table 33. SANOFI Key News & Latest Developments
Table 34. Novo Nordisk A/S Company Summary
Table 35. Novo Nordisk A/S Non-Cancerous Blood Disease Treatment Product Offerings
Table 36. Novo Nordisk A/S Non-Cancerous Blood Disease Treatment Revenue (US$, Mn) & (2018-2023)
Table 37. Novo Nordisk A/S Key News & Latest Developments
Table 38. Novartis AG Company Summary
Table 39. Novartis AG Non-Cancerous Blood Disease Treatment Product Offerings
Table 40. Novartis AG Non-Cancerous Blood Disease Treatment Revenue (US$, Mn) & (2018-2023)
Table 41. Novartis AG Key News & Latest Developments
Table 42. Pfizer Inc. Company Summary
Table 43. Pfizer Inc. Non-Cancerous Blood Disease Treatment Product Offerings
Table 44. Pfizer Inc. Non-Cancerous Blood Disease Treatment Revenue (US$, Mn) & (2018-2023)
Table 45. Pfizer Inc. Key News & Latest Developments
Table 46. Amgen Inc. Company Summary
Table 47. Amgen Inc. Non-Cancerous Blood Disease Treatment Product Offerings
Table 48. Amgen Inc. Non-Cancerous Blood Disease Treatment Revenue (US$, Mn) & (2018-2023)
Table 49. Amgen Inc. Key News & Latest Developments
Table 50. Alexion Pharmaceuticals, Inc. Company Summary
Table 51. Alexion Pharmaceuticals, Inc. Non-Cancerous Blood Disease Treatment Product Offerings
Table 52. Alexion Pharmaceuticals, Inc. Non-Cancerous Blood Disease Treatment Revenue (US$, Mn) & (2018-2023)
Table 53. Alexion Pharmaceuticals, Inc. Key News & Latest Developments
Table 54. Bayer AG Company Summary
Table 55. Bayer AG Non-Cancerous Blood Disease Treatment Product Offerings
Table 56. Bayer AG Non-Cancerous Blood Disease Treatment Revenue (US$, Mn) & (2018-2023)
Table 57. Bayer AG Key News & Latest Developments
Table 58. Bristol Myers Squibb Company Company Summary
Table 59. Bristol Myers Squibb Company Non-Cancerous Blood Disease Treatment Product Offerings
Table 60. Bristol Myers Squibb Company Non-Cancerous Blood Disease Treatment Revenue (US$, Mn) & (2018-2023)
Table 61. Bristol Myers Squibb Company Key News & Latest Developments
Table 62. F. Hoffmann-La Roche Ltd. Company Summary
Table 63. F. Hoffmann-La Roche Ltd. Non-Cancerous Blood Disease Treatment Product Offerings
Table 64. F. Hoffmann-La Roche Ltd. Non-Cancerous Blood Disease Treatment Revenue (US$, Mn) & (2018-2023)
Table 65. F. Hoffmann-La Roche Ltd. Key News & Latest Developments
Table 66. Takeda Pharmaceutical Company Limited Company Summary
Table 67. Takeda Pharmaceutical Company Limited Non-Cancerous Blood Disease Treatment Product Offerings
Table 68. Takeda Pharmaceutical Company Limited Non-Cancerous Blood Disease Treatment Revenue (US$, Mn) & (2018-2023)
Table 69. Takeda Pharmaceutical Company Limited Key News & Latest Developments
Table 70. CSL Behring Company Summary
Table 71. CSL Behring Non-Cancerous Blood Disease Treatment Product Offerings
Table 72. CSL Behring Non-Cancerous Blood Disease Treatment Revenue (US$, Mn) & (2018-2023)
Table 73. CSL Behring Key News & Latest Developments
List of Figures
Figure 1. Non-Cancerous Blood Disease Treatment Segment by Type in 2022
Figure 2. Non-Cancerous Blood Disease Treatment Segment by Application in 2022
Figure 3. Global Non-Cancerous Blood Disease Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-Cancerous Blood Disease Treatment Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Non-Cancerous Blood Disease Treatment Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-Cancerous Blood Disease Treatment Revenue in 2022
Figure 8. By Type - Global Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2029
Figure 9. By Application - Global Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2029
Figure 10. By Type - Global Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2029
Figure 12. By Application - Global Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2029
Figure 14. By Region - Global Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2029
Figure 15. By Country - North America Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2029
Figure 16. US Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2029
Figure 20. Germany Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 21. France Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2029
Figure 28. China Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 32. India Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2029
Figure 34. Brazil Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Non-Cancerous Blood Disease Treatment Revenue Market Share, 2018-2029
Figure 37. Turkey Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Non-Cancerous Blood Disease Treatment Revenue, (US$, Mn), 2018-2029
Figure 41. SANOFI Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Novo Nordisk A/S Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Novartis AG Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Pfizer Inc. Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Amgen Inc. Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Alexion Pharmaceuticals, Inc. Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Bayer AG Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Bristol Myers Squibb Company Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. F. Hoffmann-La Roche Ltd. Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Takeda Pharmaceutical Company Limited Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. CSL Behring Non-Cancerous Blood Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
